BOSTON, Mass., April 3, 2012 – OvaScience™, an innovative life science company dedicated to improving the treatment of infertility, today announced the appointment of Jeffrey D. Capello, executive vice president and chief financial officer of Boston Scientific (NYSE: BSX), to its board of directors.
“We are very pleased to welcome a seasoned life sciences leader like Jeff to OvaScience’s board of directors,” said Michelle Dipp, M.D., Ph.D., chief executive officer and co-founder of OvaScience. “Jeff’s financial expertise and perspectives will be invaluable to OvaScience as we continue the development of our novel treatments for infertility.”
As executive vice president and chief financial officer of Boston Scientific, Mr. Capello is responsible for the worldwide management of Boston Scientific’s finance, information systems, business development and corporate strategy functions. Mr. Capello joined Boston Scientific in June 2008 and served as senior vice president and chief accounting officer until March 2010. Prior to joining Boston Scientific, he was the senior vice president and chief financial officer with responsibilities for business development at PerkinElmer, Inc. (NYSE: PKI) from 2006 to 2008. Previously, he served as PerkinElmer's vice president of finance, corporate controller and treasurer from 2002 to 2006, and as vice president, finance, corporate controller, chief accounting officer and treasurer from 2001 to 2005. Prior to his tenure at PerkinElmer, Mr. Capello was a partner at PricewaterhouseCoopers LLP. Mr. Capello was a member of the board of directors of Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT acquired by GlaxoSmithKline in 2008) and served on its audit committee as both a member and its chair. Mr. Capello holds a B.S. degree in business administration from the University of Vermont and an M.B.A. degree from Harvard Business School. Mr. Capello is also a certified public accountant.
“OvaScience has assembled a world-class team of scientists and advisers dedicated to the development and commercialization of new treatment options to improve the success of in vitro fertilization,” said Mr. Capello. “I look forward to working with the OvaScience team as it advances the development of its infertility treatments for women.”
OvaScience is a privately-held fertility company focused on the discovery, development and commercialization of novel treatments for infertility. OvaScience is working to improve the treatment of female infertility based on patented technology exclusively licensed from Massachusetts General Hospital. The company’s team of scientists, physicians and advisers are recognized leaders in the field of reproductive medicine. For more information, please visit the company’s website at www.ovascience.com.